Caris Life Sciences, Inc. (NASDAQ: CAI) is a Healthcare company (Biotechnology) with a market capitalization of $6.0B. The Maz Rating grades it against the other companies in its sector.
Caris Life Sciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $21.00, Caris Life Sciences, Inc. trades at 62.5x trailing earnings, 5.7x sales and 9.3x book value, with an EV/EBITDA of 37.3. Over the last twelve months it generated about $1.0B of revenue and $96M of net income. It runs a gross margin of 69.1%, an operating margin of 13.4% and a net margin of 9.2%. It shows return on equity of 16.0%, return on invested capital of 12.5% and a free cash flow yield of 0.9%. On the balance sheet: a debt-to-equity ratio of 0.72 and a current ratio of 6.71. Over the past 52 weeks the share price ranged from $14.19 to $36.50, with a beta of 0.70.
Caris Life Sciences, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 7 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.